$310.63
7.23% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US58506Q1094
Symbol
MEDP

Medpace Target price 2024 - Analyst rating & recommendation

Medpace Classifications & Recommendation:

Buy
45%
Hold
45%
Sell
9%

Medpace Price Target

Target Price $356.50
Price $310.63
Potential
Number of Estimates 8
8 Analysts have issued a price target Medpace 2025 . The average Medpace target price is $356.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 5 Analysts recommend Medpace to buy, 5 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Medpace stock has an average upside potential 2025 of . Most analysts recommend the Medpace stock at Buy or hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion $ 1.89 2.11
29.17% 11.90%
EBITDA Margin 19.26% 21.74%
11.88% 12.90%
Net Margin 14.60% 17.46%
5.57% 19.57%

9 Analysts have issued a sales forecast Medpace 2024 . The average Medpace sales estimate is

$2.1b
Unlock
. This is
1.90% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.1b 3.01%
Unlock
, the lowest is
$2.1b 1.59%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $1.9b 29.17%
2024
$2.1b 11.90%
Unlock
2025
$2.2b 6.22%
Unlock
2026
$2.5b 12.84%
Unlock
2027
$2.9b 15.92%
Unlock
2028
$3.2b 9.79%
Unlock

9 Analysts have issued an Medpace EBITDA forecast 2024. The average Medpace EBITDA estimate is

$459m
Unlock
. This is
4.85% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$464m 6.09%
Unlock
, the lowest is
$439m 0.33%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $363m 13.82%
2024
$459m 26.32%
Unlock
2025
$477m 3.89%
Unlock
2026
$541m 13.45%
Unlock
2027
$626m 15.86%
Unlock
2028
$729m 16.33%
Unlock

EBITDA Margin

2023 19.26% 11.88%
2024
21.74% 12.90%
Unlock
2025
21.26% 2.21%
Unlock
2026
21.38% 0.56%
Unlock
2027
21.37% 0.05%
Unlock
2028
22.64% 5.94%
Unlock

8 Medpace Analysts have issued a net profit forecast 2024. The average Medpace net profit estimate is

$368m
Unlock
. This is
4.01% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$372m 5.17%
Unlock
, the lowest is
$363m 2.53%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $275m 21.98%
2024
$368m 33.77%
Unlock
2025
$389m 5.51%
Unlock
2026
$446m 14.82%
Unlock
2027
$520m 16.48%
Unlock
2028
$573m 10.22%
Unlock

Net Margin

2023 14.60% 5.57%
2024
17.46% 19.57%
Unlock
2025
17.34% 0.69%
Unlock
2026
17.64% 1.73%
Unlock
2027
17.73% 0.51%
Unlock
2028
17.80% 0.39%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 8.88 11.88
21.98% 33.78%
P/E 26.15
EV/Sales 4.34

8 Analysts have issued a Medpace forecast for earnings per share. The average Medpace <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$11.88
Unlock
. This is
4.03% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$12.01 5.17%
Unlock
, the lowest is
$11.71 2.54%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $8.88 21.98%
2024
$11.88 33.78%
Unlock
2025
$12.53 5.47%
Unlock
2026
$14.39 14.84%
Unlock
2027
$16.76 16.47%
Unlock
2028
$18.48 10.26%
Unlock

P/E ratio

Current 27.20 15.69%
2024
26.15 3.86%
Unlock
2025
24.78 5.24%
Unlock
2026
21.59 12.87%
Unlock
2027
18.53 14.17%
Unlock
2028
16.81 9.28%
Unlock

Based on analysts' sales estimates for 2024, the Medpace stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.42 7.53%
2024
4.34 1.90%
Unlock
2025
4.08 5.85%
Unlock
2026
3.62 11.38%
Unlock
2027
3.12 13.73%
Unlock
2028
2.84 8.92%
Unlock

P/S ratio

Current 4.66 1.69%
2024
4.58 1.86%
Unlock
2025
4.31 5.86%
Unlock
2026
3.82 11.38%
Unlock
2027
3.29 13.73%
Unlock
2028
3.00 8.92%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today